Cantor Fitzgerald initiated coverage of Astria Therapeutics (ATXS) with an Overweight rating and $47 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- Astria Therapeutics price target raised to $28 from $27 at Wedbush
- Astria Therapeutics Advances Clinical Trials and Financials
- Astria Therapeutics: Promising Developments and Strategic Advancements Justify Buy Rating
- Astria Therapeutics: Promising Pipeline and Strong Financials Drive Buy Rating
- Buy Rating for Astria Therapeutics: Promising Clinical Advancements and Strong Financial Position